摘要
目的分析程序性死亡分子l(PD-1)在非浸润性膀胱肿瘤患者新辅助治疗效果评估中的应用价值。方法选取天津市黄河医院2018年10月-2019年10月收治的52例非浸润性膀胱肿瘤患者,所有患者均行新辅助治疗,分析其疗效与预后情况;采用免疫组织化学染色法检测PD-1表达,统计PD-1阳性表达率,对比阳性组与阴性组患者疗效及预后的差异,以了解PD-1表达与疗效及预后的关系。结果52例患者中,完全缓解17例(32.69%),部分缓解22例(42.31%),疾病稳定9例(17.31%),疾病进展4例(7.69%),缓解率为75.00%(39/52),控制率为92.31%(48/52);复发9例,复发率为17.31%。PD-1阳性表达32例,阳性表达率为61.54%;阳性组疗效的缓解率与控制率(68.75%、87.50%)均低于阴性组(85.00%、100.00%),P<0.05,复发率(25.00%)高于阴性组(5.00%),P<0.05。结论非浸润性膀胱肿瘤患者采用新辅助治疗的效果较好,3年无进展生存率尚可;非浸润性膀胱肿瘤患者的PD-1阳性表达率较高,且其表达水平与新辅助治疗效果及预后存在一定的相关性,可作为临床疗效预测的一项重要指标。
Objective To analyze the application value of programned death molecule 1(PD-1)in the effect evaluation of neoadjuvant therapy effect in patients with non-invasive bladder tumors.Methods Select 52 norrinvasive bladder tumors treated from October 2018 to October 2019 with neoadjuvant therapy and prognosis;analyze HM expression by inmunohistochemical staining,calculate positive HM expression rate and compare the difference in efficacy and prognosis to understand the relationship between HM expression and efficacy and prognosis.Results Among 52 patients,17 had conplete remission(32.69%),partial remission 22(42.31%),stable 9(17.31%),disease progression 4(7.69%),remission rate of 75.00%(39/52),control rate of 92.31%(48/52),recurrence rate of 17.31%.There were 32 positive PD-1 patients with positive expression rate of 61.54%,remission rate and control rate(68.75%,87.50%)lower than negative(85.00%,100.00%),P<0.05,the recurrence rate(25.00%)higher than the negative group(5.00%),P<0.05.Conclusion The effect of neoadjuvant therapy in patients with nor invasive bladder tuner is better,and the 3-year progression-free survival rate is acceptable;the positive expression rate of HH in patients with non-invasive bladder tumor is higher,and its expression level is significantly different from that of neoadjuvant therapy.There is a certain correlation between the effect and prognosis,and it can be used as an important indicator for the prediction of clinical effect.
作者
柴旺
高静
Chai Wang;Gao Jing(Department of Urology,Tianjin Yellow River Hospital,Tianjin 300110,China)
出处
《首都食品与医药》
2022年第16期41-43,共3页
Capital Food Medicine
